Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

In 2000, guidelines from the American Society of Clinical Oncology (ASCO) recommended that HER2 testing should be performed on all newly diagnosed breast cancer patients, [14] to assess whether ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...

Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer involves tumor cells that test positive for hormone receptors and negative for HER2 proteins. Cancer cells with estrogen ...

Key side effects of Enhertu include myelosuppression, gastrointestinal issues, and interstitial pneumonitis, requiring careful monitoring. The approval highlights the importance of accurate HER2 ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...